Phase-2 multicenter study results of Ublituximab, a novel glycoengineered antiCD20 monoclonal Antibody (mAb), in patients with Relapsing Multiple Sclerosis (RMS)
EUROPEAN JOURNAL OF NEUROLOGY（2018）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined